ArticleKidney medicine2026
Interleukin-17 Inhibitors and the Potential Association of Systemic Lupus Erythematosus.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review.Dermatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Some patients with psoriasis develop lupus erythematosus-like side effects after treatment with interleukin (IL)-17 inhibitors. Whether use of IL-17 inhibitors increases the risk of systemic lupus erythematosus (SLE) remains unclear. This study explores the potential relationship between use of IL-17 inhibitors and the onset of SLE. Study Design: Case reports, cohort study, pharmacovigilance study, and 2-sample Mendelian randomization (MR). Setting & Participants: Two patients with psoriasis who developed SLE and lupus nephritis (LN) after using IL-17 inhibitors, clinical data from 7,367 patients with psoriasis at Jiangsu Province Hospital, adverse drug reaction reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS), and data from genome-wide association studies related to IL-17A/IL-17 receptor A and SLE. Exposures: Use of IL-17 inhibitors. Outcomes: Development of SLE. Analytical Approach: Fisher exact test, reporting odds ratio (ROR), and inverse variance weighting. Results: Two Chinese patients developed SLE and LN symptoms 2-4 months after receiving IL-17 inhibitor treatment for psoriasis. Kidney biopsy confirmed LN in both patients. A single-center cohort study revealed a significantly higher incidence of lupus among psoriasis patients using IL-17 inhibitors compared to non-users (1.626 vs 0.085 per 1,000 person-years; relative risk, 19.10; 95% confidence intervals [CIs], 1.99-183.47). Pharmacovigilance analysis of the FAERS database indicated an elevated reporting risk of SLE-related adverse reactions associated with IL-17 inhibitors (ROR, 1.62; 95% CI, 1.35-1.95). However, a meta-analysis of MR studies showed that IL-17A (OR, 1.06; 95% CI, 0.89-1.26; Limitations: The case reports and cohort study focus on Asian populations, whereas the FAERS and MR analyses use data from American and European populations. Conclusions: Use of IL-17 inhibitors might be associated with the increased risk of SLE-like side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.